At last week's BioStock Investor Meeting, femtech company Pharmiva was first out to present. CEO Anna Linton talked about Pharmiva's product against bacterial vaginosis, Vernivia, which was launched in Sweden at the end of 2021. Linton also elaborated on the company's expansion strategy and the current rights issue that will support a global launch.

See the presentation at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-pharmiva-presents/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/pharmiva/r/biostock-investor-meeting--pharmiva-presents,c3632860

(c) 2022 Cision. All rights reserved., source Press Releases - English